Shlomo Shalev - XTL Biopharmaceutica CEO Director
| XTLB Stock | USD 1.85 0.03 1.60% |
Insider
Shlomo Shalev is CEO Director of XTL Biopharmaceuticals Ltd
| Age | 62 |
| Address | 26 Ben-Gurion St., Ramat Gan, Israel, 5112001 |
| Phone | 972 3 611 6600 |
| Web | https://www.xtlbio.com |
XTL Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (0.1378) % which means that it has lost $0.1378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1307) %, meaning that it created substantial loss on money invested by shareholders. XTL Biopharmaceutica's management efficiency ratios could be used to measure how well XTL Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. As of December 3, 2024, Return On Tangible Assets is expected to decline to -0.0009. The current year's Return On Capital Employed is expected to grow to -0.33. At present, XTL Biopharmaceutica's Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 4.6 M, whereas Total Assets are forecasted to decline to about 2.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MPA MD | Unicycive Therapeutics | 51 | |
| FMEDSCI MD | Candel Therapeutics | 62 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Susan Kahlert | Senti Biosciences | N/A | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Inf MD | Candel Therapeutics | 64 | |
| MD MS | Candel Therapeutics | 53 | |
| Jason Amello | Candel Therapeutics | 56 | |
| Ileen Winick | Candel Therapeutics | N/A | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Wilson Wong | Senti Biosciences | N/A | |
| Seshu Tyagarajan | Candel Therapeutics | 56 | |
| LLM JD | Candel Therapeutics | 63 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| James Foster | Virax Biolabs Group | 39 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Francesca MD | Candel Therapeutics | 46 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Philip Lee | Senti Biosciences | 42 | |
Management Performance
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.14 |
XTL Biopharmaceuticals Leadership Team
Elected by the shareholders, the XTL Biopharmaceutica's board of directors comprises two types of representatives: XTL Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XTL. The board's role is to monitor XTL Biopharmaceutica's management team and ensure that shareholders' interests are well served. XTL Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XTL Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Itay CPA, Chief Officer | ||
| Itay Weinstein, Chief Officer | ||
| Shlomo Shalev, CEO Director | ||
| Ronen Kantor, Company Sec |
XTL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XTL Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 7.56 M | ||||
| Shares Outstanding | 5.45 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 1.92 % | ||||
| Number Of Shares Shorted | 75.24 K | ||||
| Price To Earning | 4.50 X | ||||
| Price To Book | 3.73 X | ||||
| EBITDA | (764 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.